MRNA vs NBIX
Moderna, Inc. and Neurocrine Biosciences, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | MRNA | NBIX |
|---|---|---|
| Revenue | $1.9B | $2.9B |
| Net income | $-2.8B | $478.6M |
| Gross margin | 55.3% | 98.2% |
| Net margin | −145.2% | 16.7% |
| Return on equity | −28.9% | 16.4% |
| Diluted EPS | −$7.26 | $4.67 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | $-2.1B | $748.7M |
| Equity | $8.7B | $3.3B |
| Net debt / equity | −0.23× | — |
| Current ratio | 3.29× | 3.39× |
| Revenue CAGR 5y | 19.3% | 22.3% |
| Profit CAGR 5y | — | 3.3% |
NBIX bills 1.5× the revenue of MRNA, and MRNA closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | MRNA | NBIX |
|---|---|---|
| FY2025 | $1.9B | $2.9B |
| FY2024 | $3.2B | $2.4B |
| FY2023 | $6.8B | $1.9B |
| FY2022 | $19.3B | $1.5B |
| FY2021 | $18.5B | $1.1B |
| FY2020 | $803.0M | $1.0B |
| FY2019 | $60.0M | $788.1M |
| FY2018 | $135.1M | $451.2M |
| FY2017 | $205.8M | $161.6M |
| FY2016 | $108.4M | $15.0M |
Net income by year
Bottom line
| Fiscal year | MRNA | NBIX |
|---|---|---|
| FY2025 | $-2.8B | $478.6M |
| FY2024 | $-3.6B | $341.3M |
| FY2023 | $-4.7B | $249.7M |
| FY2022 | $8.4B | $154.5M |
| FY2021 | $12.2B | $89.6M |
| FY2020 | $-747.0M | $407.3M |
| FY2019 | $-514.0M | $37.0M |
| FY2018 | $-384.7M | $21.1M |
| FY2017 | $-255.9M | $-142.5M |
| FY2016 | $-216.2M | $-141.1M |
Advertisement
AdSense · Rectangle 336×280
More in this industry